Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $0.00 and traded as high as $0.0003. Nascent Biotech shares last traded at $0.0003, with a volume of 7,500 shares changing hands.
Nascent Biotech Stock Down 40.0%
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
See Also
- Five stocks we like better than Nascent Biotech
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Unlocked: Elon Musk’s Next Big IPO
- My Epstein Story
- What a Former CIA Agent Knows About the Coming Collapse
- Gilder: Don’t Buy AI Stocks, Do This Instead
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
